fashion -WSS

fashion

author：hotspot 2025-09-28 00:53:37 - browse：438

Adobe

You didn’t need machine learning to make one prediction about the year’s biggest conference for health care investors, which was held in San Francisco last week. It was going to rain.

Recursion, a biotechnology firm that uses machine learning for drug development and that was announcing that it is rolling out AI-driven drug discovery software with tech giant Nvidia, decided to seize the moment. As the heavens opened, Recursion employees handed out black umbrellas emblazoned with the Recursion logo and lined with neon images of cells. It was one of a series of publicity grabs from the company, including a satellite event featuring Nvidia’s famous CEO, Jensen Huang, who has become a Wall Street rock star as his company’s stock has exploded due to rising expectations for AI, reaching a $1 trillion market value, the sixth highest in the world.

Seeing the square outside the Westin St. Francis, where the J.P. Morgan Healthcare Conference has been held for 42 years, fill with Recursion’s umbrellas was a little like seeing the message that AI was ready for its debut come to life. But it was also true that not everyone was ready to embrace that message.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Testing for cancer recurrence creates a new limbo for patients

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

The FDA weighs the risks of candy

eGenesis tests gene

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

knowledge

fashion

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

WHO may add ‘noma' to its list of neglected tropical diseases

What does generative AI mean for health care? We asked experts

Medicare Advantage today, explained in one chart

Medicare details structure of new drug price negotiation program

Prior authorization will have to move faster under new Biden rule

As demand for Covid shots wanes, Moderna seeks its next success

Hospitals warn Medicare's drug payment fix is ‘unlawful’

What does generative AI mean for health care? We asked experts

Humana cuts profit projections as Medicare Advantage costs soar

leisure time

The FDA weighs the risks of candy

Prior authorization will have to move faster under new Biden rule

Humana cuts profit projections as Medicare Advantage costs soar

Copay coupons to count toward deductibles, after Biden court move

Why Sanofi got shellacked over its spinoff

AI generated plenty of interest at JPM but not a lot of trust

focus

focus

leisure time

explore